ZA200807616B - Benzimidazoles which have activity at M1 receptor and their uses in medicine - Google Patents
Benzimidazoles which have activity at M1 receptor and their uses in medicineInfo
- Publication number
- ZA200807616B ZA200807616B ZA200807616A ZA200807616A ZA200807616B ZA 200807616 B ZA200807616 B ZA 200807616B ZA 200807616 A ZA200807616 A ZA 200807616A ZA 200807616 A ZA200807616 A ZA 200807616A ZA 200807616 B ZA200807616 B ZA 200807616B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzimidazoles
- receptor
- medicine
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0605786.3A GB0605786D0 (en) | 2006-03-22 | 2006-03-22 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200807616B true ZA200807616B (en) | 2010-07-28 |
Family
ID=36383995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200807616A ZA200807616B (en) | 2006-03-22 | 2008-09-04 | Benzimidazoles which have activity at M1 receptor and their uses in medicine |
Country Status (22)
Country | Link |
---|---|
US (3) | US20100280071A1 (fr) |
EP (1) | EP2004182B1 (fr) |
JP (1) | JP5256187B2 (fr) |
KR (1) | KR20090015027A (fr) |
CN (2) | CN103058990A (fr) |
AR (1) | AR059977A1 (fr) |
AU (1) | AU2007228716A1 (fr) |
BR (1) | BRPI0708999A2 (fr) |
CA (1) | CA2646896A1 (fr) |
CR (1) | CR10314A (fr) |
EA (1) | EA200870360A1 (fr) |
GB (1) | GB0605786D0 (fr) |
IL (1) | IL194206A0 (fr) |
MA (1) | MA30324B1 (fr) |
MX (1) | MX2008012160A (fr) |
NO (1) | NO20084048L (fr) |
NZ (1) | NZ595738A (fr) |
PE (1) | PE20080007A1 (fr) |
SG (1) | SG170752A1 (fr) |
TW (1) | TW200813004A (fr) |
WO (1) | WO2007107565A1 (fr) |
ZA (1) | ZA200807616B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
GB0706167D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706187D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
JP2010539217A (ja) | 2007-09-20 | 2010-12-16 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬としてのそれらの使用 |
US8299257B2 (en) | 2007-09-20 | 2012-10-30 | Glaxo Group Limited | Compounds which have activity at M1receptor and their uses in medicine |
WO2009124883A1 (fr) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Nouveaux 1,3-dihydro-benzoimidazol-2-ones utilisés en tant qu’agonistes m1 |
GB0817982D0 (en) * | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
JP5990980B2 (ja) * | 2012-04-02 | 2016-09-14 | 大日本印刷株式会社 | オランザピンの中間体の製造方法 |
CA3008272A1 (fr) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methodes de traitement du cancer |
JP6958820B2 (ja) | 2015-12-14 | 2021-11-02 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がんを処置する方法 |
CN108883091A (zh) | 2015-12-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗免疫缺陷病的方法 |
CN107129439A (zh) * | 2016-02-26 | 2017-09-05 | 中国科学院大连化学物理研究所 | 一种化合物、毒蕈碱m受体拮抗剂、组合物及应用 |
CN109153722A (zh) | 2016-04-08 | 2019-01-04 | X4 制药有限公司 | 用于治疗癌症的方法 |
WO2017223229A1 (fr) * | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Inhibiteurs de cxcr4 et leurs utilisations |
ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN113637001A (zh) * | 2021-08-09 | 2021-11-12 | 安康市农业科学研究院 | 一种氟哌利多中间体的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4040300A1 (de) * | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
CA2200468A1 (fr) * | 1994-10-27 | 1996-05-09 | Wayne J. Thompson | Antagonistes de muscarine |
AU7478396A (en) * | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
JPH10330377A (ja) * | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
IL137149A0 (en) * | 1998-01-19 | 2001-07-24 | Pfizer | 4-(2-keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists |
JP2003524634A (ja) * | 1999-12-06 | 2003-08-19 | ユーロ−セルティーク,エス.エイ. | ノシセプチン受容体親和性を有するベンズイミダゾール化合物 |
WO2004089942A2 (fr) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Derives de benzimidazolidinone utilises en tant qu'agents muscariniques |
EP1515722A4 (fr) * | 2002-06-17 | 2006-06-21 | Merck & Co Inc | Compositions ophtalmiques destinees a traiter l'hypertension oculaire |
KR20050087832A (ko) * | 2002-12-13 | 2005-08-31 | 스미스클라인 비참 코포레이션 | Ccr5 길항제로서 피페리딘 유도체 |
US8288413B2 (en) * | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
-
2006
- 2006-03-22 GB GBGB0605786.3A patent/GB0605786D0/en not_active Ceased
-
2007
- 2007-03-20 EA EA200870360A patent/EA200870360A1/ru unknown
- 2007-03-20 MX MX2008012160A patent/MX2008012160A/es not_active Application Discontinuation
- 2007-03-20 AU AU2007228716A patent/AU2007228716A1/en not_active Abandoned
- 2007-03-20 EP EP07727115.3A patent/EP2004182B1/fr active Active
- 2007-03-20 TW TW096109422A patent/TW200813004A/zh unknown
- 2007-03-20 CA CA002646896A patent/CA2646896A1/fr not_active Abandoned
- 2007-03-20 CN CN2012102916757A patent/CN103058990A/zh active Pending
- 2007-03-20 SG SG201102019-5A patent/SG170752A1/en unknown
- 2007-03-20 US US12/293,625 patent/US20100280071A1/en not_active Abandoned
- 2007-03-20 PE PE2007000306A patent/PE20080007A1/es not_active Application Discontinuation
- 2007-03-20 AR ARP070101119A patent/AR059977A1/es not_active Application Discontinuation
- 2007-03-20 KR KR1020087025705A patent/KR20090015027A/ko not_active Application Discontinuation
- 2007-03-20 JP JP2009500852A patent/JP5256187B2/ja not_active Expired - Fee Related
- 2007-03-20 WO PCT/EP2007/052638 patent/WO2007107565A1/fr active Application Filing
- 2007-03-20 BR BRPI0708999-6A patent/BRPI0708999A2/pt not_active Application Discontinuation
- 2007-03-20 CN CN2007800188235A patent/CN101448495B/zh not_active Expired - Fee Related
- 2007-03-20 NZ NZ595738A patent/NZ595738A/xx not_active IP Right Cessation
-
2008
- 2008-09-04 ZA ZA200807616A patent/ZA200807616B/xx unknown
- 2008-09-18 IL IL194206A patent/IL194206A0/en unknown
- 2008-09-23 NO NO20084048A patent/NO20084048L/no not_active Application Discontinuation
- 2008-09-23 CR CR10314A patent/CR10314A/es not_active Application Discontinuation
- 2008-10-07 MA MA31270A patent/MA30324B1/fr unknown
-
2011
- 2011-10-27 US US13/282,610 patent/US20120041028A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/584,956 patent/US20120316202A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ595738A (en) | 2012-11-30 |
US20120316202A1 (en) | 2012-12-13 |
KR20090015027A (ko) | 2009-02-11 |
CA2646896A1 (fr) | 2007-09-27 |
CN101448495B (zh) | 2013-05-08 |
EA200870360A1 (ru) | 2009-02-27 |
CN103058990A (zh) | 2013-04-24 |
MX2008012160A (es) | 2008-10-03 |
EP2004182A1 (fr) | 2008-12-24 |
TW200813004A (en) | 2008-03-16 |
JP2009530347A (ja) | 2009-08-27 |
IL194206A0 (en) | 2009-08-03 |
JP5256187B2 (ja) | 2013-08-07 |
GB0605786D0 (en) | 2006-05-03 |
PE20080007A1 (es) | 2008-03-16 |
CN101448495A (zh) | 2009-06-03 |
AR059977A1 (es) | 2008-05-14 |
BRPI0708999A2 (pt) | 2011-06-21 |
AU2007228716A1 (en) | 2007-09-27 |
MA30324B1 (fr) | 2009-04-01 |
NO20084048L (no) | 2008-10-20 |
CR10314A (es) | 2008-12-01 |
EP2004182B1 (fr) | 2013-05-08 |
WO2007107565A1 (fr) | 2007-09-27 |
US20120041028A1 (en) | 2012-02-16 |
SG170752A1 (en) | 2011-05-30 |
US20100280071A1 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL194206A0 (en) | Benzimidazoles which have activity at m1 receptor and their uses in medicine | |
IL275854A (en) | Pharmaceutical composition and its administration | |
ZA200802167B (en) | Compounds which have activity at M1 Receptor and their uses in medicine | |
EP2203158A4 (fr) | Formulations pharmaceutiques comprenant du telmisartan et de l'hydrochlorotiazide | |
IL184563A (en) | Pharmaceutical foam formulations and their use | |
GB0803072D0 (en) | Solid pharmaceutical and vaccien dose | |
GB2443823B (en) | Devices and methods for use in construction | |
SI2154966T1 (sl) | Benzimidazoli in njihovi farmacevtski sestavki | |
EP2132133A4 (fr) | Administration de médicament particulaire | |
IL194751A0 (en) | Drugs and uses | |
GB0805477D0 (en) | Pyrimidines triazines and their use as pharmaceutical agents | |
EP2068776A4 (fr) | Endoprothèse vasculaire et son dispositif de mise en place | |
ZA201004261B (en) | Anthelmintic agents and their use | |
GB0615834D0 (en) | Polymeric micellar clusters and their uses in formulating drugs | |
IL204528A (en) | Pharmaceutical dosage forms for immediate sustained release of metadoxin | |
EP2128154A4 (fr) | Composé de benzimidazole et utilisation pharmaceutique de celui-ci | |
GB2443336B (en) | Spiruchostatin analogues and their medicinal use | |
ZA200903574B (en) | 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists | |
GB0610090D0 (en) | Particulate drug compositions and their uses | |
GB2460178B (en) | Depsipeptides and their therapeutic use | |
GB0614365D0 (en) | Pharmaceutical compositions and their use | |
GB2460181B (en) | Depsipeptides and their therapeutic use | |
EP2067480A4 (fr) | Récepteur de la muscline et son utilisation | |
EP2273266A4 (fr) | Récepteur de parasporine-1 et son utilisation | |
EP2189451A4 (fr) | Dérivés de benzamide, leur préparation et leurs utilisations pour un médicament |